On August 7, Novo-Nordisk A/S rose 3.02% in regular trading, trading at $45.885/share, with turnover of $421 million. The stock continued its rebound driven by strong Q2 results and a favorable patent ruling in the Netherlands.

On the news front, the District Court of The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., ruling that its compounded semaglutide nasal spray infringed Novo Nordisk's supplementary protection certificate. The court ordered Ceban to immediately cease sales, reinforcing Novo Nordisk's intellectual property moat around its core GLP-1 franchise. Meanwhile, BMO raised its target price on the stock from $45 to $47.

The patent victory follows Q2 earnings reported on August 5, in which adjusted EPS of $0.96 beat the consensus estimate of $0.81 by 18.5%, while sales of $12.209 billion exceeded the $11.35 billion estimate. The company also raised full-year sales and operating profit guidance, primarily driven by higher GLP-1 product sales expectations. The stock had previously fallen nearly 10% after its ziltivekimab cardiovascular drug failed a Phase 3 trial, and the current rebound reflects a repricing of the resilience of its core obesity and diabetes business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)